Medtronic PLC is acquiring Stimgenics, the developer of a spinal cord stimulation waveform designed to interrupt pain signals on a cellular level, the companies announced on 8 January.
Medtronic will pay an undisclosed figure for Bloomington, IL-based Stimgenics to acquire the “know-how” and the patents behind its differential target multiplexed (DTM) spinal cord stimulation waveform, according to Marshall...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?